Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?

Coronavirus 2019 disease (COVID-19) is associated with coagulation dysfunction that predisposes patients to an increased risk for both arterial (ATE) and venous thromboembolism (VTE) and consequent poor prognosis; in particular, the incidence of ATE and VTE in critically ill COVID-19 patients can re...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavoni, Vittorio, Gianesello, Lara, Horton, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8109223/
https://www.ncbi.nlm.nih.gov/pubmed/33973157
http://dx.doi.org/10.1007/s11239-021-02470-y
_version_ 1783690213352013824
author Pavoni, Vittorio
Gianesello, Lara
Horton, Andrew
author_facet Pavoni, Vittorio
Gianesello, Lara
Horton, Andrew
author_sort Pavoni, Vittorio
collection PubMed
description Coronavirus 2019 disease (COVID-19) is associated with coagulation dysfunction that predisposes patients to an increased risk for both arterial (ATE) and venous thromboembolism (VTE) and consequent poor prognosis; in particular, the incidence of ATE and VTE in critically ill COVID-19 patients can reach 5% and 31%, respectively. The mechanism of thrombosis in COVID-19 patients is complex and still not completely clear. Recent literature suggests a link between the presence of antiphospholipid antibodies (aPLs) and thromboembolism in COVID-19 patients. However, it remains uncertain whether aPLs are an epiphenomenon or are involved in the pathogenesis of the disease.
format Online
Article
Text
id pubmed-8109223
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-81092232021-05-11 Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon? Pavoni, Vittorio Gianesello, Lara Horton, Andrew J Thromb Thrombolysis Article Coronavirus 2019 disease (COVID-19) is associated with coagulation dysfunction that predisposes patients to an increased risk for both arterial (ATE) and venous thromboembolism (VTE) and consequent poor prognosis; in particular, the incidence of ATE and VTE in critically ill COVID-19 patients can reach 5% and 31%, respectively. The mechanism of thrombosis in COVID-19 patients is complex and still not completely clear. Recent literature suggests a link between the presence of antiphospholipid antibodies (aPLs) and thromboembolism in COVID-19 patients. However, it remains uncertain whether aPLs are an epiphenomenon or are involved in the pathogenesis of the disease. Springer US 2021-05-10 2021 /pmc/articles/PMC8109223/ /pubmed/33973157 http://dx.doi.org/10.1007/s11239-021-02470-y Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Pavoni, Vittorio
Gianesello, Lara
Horton, Andrew
Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?
title Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?
title_full Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?
title_fullStr Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?
title_full_unstemmed Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?
title_short Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?
title_sort antiphospholipid antibodies in critically ill covid-19 patients with thromboembolism: cause of disease or epiphenomenon?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8109223/
https://www.ncbi.nlm.nih.gov/pubmed/33973157
http://dx.doi.org/10.1007/s11239-021-02470-y
work_keys_str_mv AT pavonivittorio antiphospholipidantibodiesincriticallyillcovid19patientswiththromboembolismcauseofdiseaseorepiphenomenon
AT gianesellolara antiphospholipidantibodiesincriticallyillcovid19patientswiththromboembolismcauseofdiseaseorepiphenomenon
AT hortonandrew antiphospholipidantibodiesincriticallyillcovid19patientswiththromboembolismcauseofdiseaseorepiphenomenon

Ejemplares similares